Original Article

Left ventricular assist device (LVAD) program in Chile: first successful experience in South America

Oneglio Pedemonte¹²³, Andres Vera¹²³, Lorenzo Merello¹²³, Manuel Novajas¹², Fernando Aranda², Julio Ibarra¹², Jose A. Muñoz¹², Javier Alburquerque¹², Paulina Espinoza¹, Felipe Cárdenas², Ernesto Aránguiz-Santander¹²³

¹Department of Cardiovascular Surgery, Hospital Gustavo Fricke, Viña del Mar, Chile; ²Department of Cardiovascular Diseases, Universidad de Valparaíso, Valparaíso, Chile; ³Fundación Cardiovascular Dr. Jorge Kaplan Meyer, Viña del Mar, Chile

Contributions: (I) Conception and design: All authors; (II) Administrative support: O Pedemonte, A Vera, L Merello, P Espinoza, F Cárdenas, E Aránguiz-Santander; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: O Pedemonte, A Vera, L Merello, J Ibarra, P Espinoza, F Cárdenas, E Aránguiz-Santander; (V) Data analysis and interpretation: O Pedemonte, L Merello, M Novajas, JA Muñoz, F Cárdenas, E Aránguiz-Santander; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Oneglio Pedemonte, MD. Assistant Professor of Intensive Medicine, Hospital Gustavo Fricke, Alvares 1532, Viña del Mar, Chile. Email: onegliopedemontev@hotmail.com.

Background: The need to have a variety of tools to deal with end-stage heart failure (ES-HF), along with the limited heart transplantation availability encouraged us to create a pilot Left ventricular assist device (LVAD) program in a public health care system hospital in Chile.

Methods: A retrospective analysis of the first nine patients of an ongoing LVAD program initiated on August 2013 was performed, completing an average of 30 months of follow-up. The most important events regarding to morbidity and mortality are described.

Results: Nine patients with ES-HF underwent LVAD implantation surgery; one of them died 23 days after surgery and another died after 11 months. One patient successfully underwent heart transplantation after 16 months of HeartWare ventricular assist device (HVAD) support; the other six patients remain in the program and have an average follow-up of 846 days at the time of this study (range, 23–1,481 days). The survival rate at 6, 12 and 18 months follow-up was 89%, 78% and 78% respectively.

Conclusions: This new pioneering LVAD program in Chile has been successful and now constitutes a vital adjunct to all who work in heart transplantation and ES-HF programs. It offers an effective therapeutic alternative when there is a severe donor shortage, in cases of atypical blood types, emergencies, exceptional cases with contraindication for heart transplantation or when there is important donor-receiver size mismatch.

Keywords: HeartWare ventricular assist device (HVAD®); end-stage heart failure (ES-HF); descriptive study

Submitted Oct 27, 2017. Accepted for publication Feb 06, 2018.
doi: 10.21037/jtd.2018.02.83
View this article at: http://dx.doi.org/10.21037/jtd.2018.02.83

Introduction

Chile has a vast history of cardiac surgery, particularly in the field of heart transplantation (HT). As a matter of fact, the year 2018 marks the 50th anniversary of the first HT surgery in the country, performed on July 28th, 1968 by Dr. Jorge Kaplan, in the region of Valparaiso only 6 months after the world’s first HT by Dr. Christiaan Barnard in South Africa. A few years later, Dr. Kaplan created the department of cardiovascular surgery in our hospital, located in the city of Viña del Mar. This unit is now responsible for the treatment of patients diagnosed with end-stage heart failure (ES-HF) over a population of more than 10 million beneficiaries of the Chilean public...
health care system. In over 20 years since the creation of this program more than 100 HT surgeries have been performed, representing the most important figure in the country. The main reason for the reduced number of transplants is the low donation rate, which hardly reaches a rate of 7 per million habitants, of which only 20% become heart donors (1). This limitation implies that many patients die while waiting on the national HT list. This fact motivated our team to search for new treatment alternatives for patients who arrived at our hospital seeking for a solution to their ES-HF.

The new technologies in ventricular assist devices developed during recent years and the better outcomes in survival rates have allowed an important increase in device implantations worldwide (2,3).

We were particularly interested in a third-generation pump, the HeartWare ventricular assist device (HVAD®) (Heart-Ware Inc., USA: HVAD) a small (50 mL) volume, continuous flow-centrifugal pump, with a magnetically and hydrodynamically suspended impeller, with a maximum external diameter of 53 mm and a total weight of 140 grams (4).

There have been reports of promising results with less invasive surgical techniques, allowing a reduction in the number of complications and better preservation of right ventricular (RV) function, usually a very critical factor in patient outcomes, as evidenced by the publications from the Hannover group (5-7).

Our first goal was to obtain funding to install the first two devices and at the same time to present the LVAD project to the sanitary authorities of the country, with the aim of starting a long-term official program. As a result, nine devices have been implanted (8) to date and it is therefore important to review the results. Despite the small number of patients documented in this article, it constitutes the first and most comprehensive review of experience with LVAD implantation in South America.

**Methods**

**Patients**

Nine patients (seven males and two females) with a mean age 39±15 years of age, functional class III to IV of the New York Heart Association (NYHA), were chosen for this pilot program. All patients received conventional therapy; eight were on the national HT list including one patient with history of femoral osteosarcoma and carrier of hepatitis C was considered for LVAD as destination therapy. All patients signed the informed consent approved by the Ethics Committee of Gustavo Fricke Hospital in Viña del Mar (Table 1).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
<th>Patient 6</th>
<th>Patient 7</th>
<th>Patient 8</th>
<th>Patient 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>30</td>
<td>53</td>
<td>35</td>
<td>59</td>
<td>15</td>
<td>57</td>
<td>27</td>
<td>37</td>
<td>55</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>Male</td>
<td>Male</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>BSA (m²)</td>
<td>1.65</td>
<td>1.74</td>
<td>2.09</td>
<td>1.88</td>
<td>1.29</td>
<td>2.34</td>
<td>1.75</td>
<td>1.55</td>
<td>1.92</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>20.1</td>
<td>22.1</td>
<td>31.5</td>
<td>23.6</td>
<td>17.8</td>
<td>30.1</td>
<td>21.6</td>
<td>18.2</td>
<td>24.5</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>DCM</td>
<td>Isquemic CM</td>
<td>Isquemic CM</td>
<td>DCM</td>
<td>DCM</td>
<td>Isquemic CM</td>
<td>dHCM</td>
<td>CICM</td>
<td>Isquemic CM</td>
</tr>
<tr>
<td>LVDD (mm)</td>
<td>77</td>
<td>95</td>
<td>89</td>
<td>76</td>
<td>80</td>
<td>97</td>
<td>72</td>
<td>70</td>
<td>80</td>
</tr>
<tr>
<td>LVEF%</td>
<td>17</td>
<td>17</td>
<td>15</td>
<td>20</td>
<td>22</td>
<td>18</td>
<td>12</td>
<td>28</td>
<td>17</td>
</tr>
<tr>
<td>Cl (Lt/min)</td>
<td>178</td>
<td>70</td>
<td>101</td>
<td>70</td>
<td>99</td>
<td>133</td>
<td>91</td>
<td>70</td>
<td>81</td>
</tr>
<tr>
<td>Preoperative support</td>
<td>No</td>
<td>No</td>
<td>IABP</td>
<td>No</td>
<td>ECMO</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>NYHA class</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Internacs</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

BSA, body surface area; BMI, body mass index; LVDD: left ventricular diastolic diameter; LVEF, left ventricular ejection fraction; Cl, clearance; NYHA, New York Heart Association; DCM, dilated cardiomyopathy; dHCM, dilated phase hypertrophic cardiomyopathy; CM, cardiomyopathy; CICM, chemotherapy induced cardiomyopathy; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation.
All patients underwent a thorough evaluation by a multidisciplinary ES-HF and HT Committee, which decides and defines the indication and enrollment of patients in the national HT list. During LVAD implantation, one patient was classified as Intermacs profile 1, another as Intermacs profile 2, two as Intermacs profile 3 and five as Intermacs profile 4.

The etiology of ES-HF was ischemic cardiomyopathy in four patients, idiopathic cardiomyopathy in three patients, hypertrophic cardiomyopathy in dilated phase in one patient and chemotherapy induced cardiomyopathy in another patient. The mean ejection fraction was 18%. One patient had ECMO support 10 days prior to the intervention; another patient was assisted by balloon counter-pulsation for 72 hours before the surgery.

All patients received an infusion of levosimendan at a dosage of 0.1 µg/kg/min before surgery and the rest of the preoperative preparation was done according to the established local protocol for patients who undergo cardiac surgery.

Surgical technique

The HVAD® consists of a continuous-flow centrifugal pump, a 21-mm diameter integrated inflow cannula, an outflow Dacron graft, an electrical wire connected to a power source and an external controller that monitors and controls the device. In its interior there is an impeller that suspends and rotates by hydrodynamic and passive magnetic forces, levitating to avoid friction with an adjustable speed between 1,800 and 4,000 rpm, generating flows up to 10 liters per minute. A titanium sewing ring covered in polyester is attached to the apex of the left ventricle (LV) fixing the pump to its position. The externally worn controller—transported by the patient—displays information on speed, flow and energy consumption. It also displays alarms and recommended troubleshooting. The controller is powered by two lithium ion batteries, an AC adaptor, or a DC adaptor for cars.

The preparation for surgery is similar to a conventional cardiac surgery. There are two surgical incisions; the first one is 8-cm long and located under the left side, 5th intercostal space and the second one is an “L” shaped 6-cm long incision at the level of the sternal manubrium. The LV is approached through the left thoracotomy, installing the sewing ring to the anterior side near the apex (9). The outflow graft with the strain relief is attached to the ascending aorta through the second incision. The integrated inflow cannula is installed inside the LV and directed towards the mitral valve, to receive the blood flow that comes from the left atrium (Figure 1). The driveline emerges from the pump and throughout a subcutaneous course in the abdomen; it then exits the patient’s skin at the left flank. It then connects to the controller and two batteries that the patient transports in a specially designed bag. The final installation has been illustrated in Figure 2.

Results

Surgical results

All the implants were performed without major setbacks. In eight patients the pump was implanted through the left anterolateral thoracotomy and one patient required a full sternotomy approach due to her precarious hemodynamic condition prior to surgery (Intermacs profile 1).

The mean surgery time was 213±26 minutes. The cardiopulmonary bypass time was 67±20 minutes. The initial LVAD flow was about 5 liters per minute, achieved with a speed of 2,700 rpm (Table 2).

In one patient a supplementary mini-thoracotomy was performed to expose the left atrium and explore a suspected thrombus formation that finally corresponded to a false
Post-operative follow-up

One patient (Intermacs profile 1) died 23 days after the implantation surgery due to multiple organ failure. Another patient died after 11 months due to stroke complications; two patients required surgical re-exploration due to bleeding complications in the immediate postoperative period.

Eight patients were extubated within the first 48 hours after surgery. All patients received postoperative adrenalin infusion, adjusting dosage until achieving acceptable hemodynamic conditions and adequate performance of the right ventricle. Long-term survival rate at 6, 12 and 18 months follow-up in this series was 89%, 78% and 78% respectively, similar to the success rate reported in the ReVOLVE study (10).

The most frequent complication observed during follow-up was gastrointestinal bleeding, followed by driveline infections and stroke. One case of device thrombosis was successfully resolved by a single dose of alteplase.

One patient developed outflow graft stenosis that was successfully resolved through endovascular implantation of a 10-mm stent. There were no patients who required extraordinary mechanical support or HVAD® exchange. At the time of this report, five patients were classified as NYHA class I and one with NYHA II (Table 3).

Discussion

Mechanical circulatory support for patients with advanced heart failure was initiated in the 1960s, however there was no significant progress during the following 4 decades (11). With the incorporation of new LVADs, the number of implants has increased in patients waiting for heart transplantation and as a destination therapy (2,12). The development of LVAD HeartMate II® in the year 2003, increased the number of implants in developed countries reaching more than 20,000 patients with LVADs by June 2017, according the last Intermacs registry report (13).

All patients reported in this study had a waiting time for heart transplantation of over 6 months, and most of them were classified as Intermacs profile 3, with high risk of hospitalization and death. This background prompted the team to create this program with the collaboration of experts from the Hannover Medical School, who guided the first implants and advised on the use of minimally invasive surgical technique developed by Schmitto et al. (8,9,14,15), that offers better survival rate, less morbidity and lower hospitalization costs (5) and a reduction of the complexity in redo operations for heart transplantation (16).

The previously described technique allows maintaining an intact pericardium, preventing dilatation and dysfunction of the RV during the weaning of cardiopulmonary bypass, reducing the need for drugs and/or mechanical support; thus, simplifying the postoperative management and reducing the postoperative hospital stay. One of the central goals of preoperative care is the improvement of contractibility of both ventricles and the reduction in pulmonary hypertension. That objective was achieved by the infusion of levosimendan, whose beneficial effects persist for several days after infusion (17). During surgery, it was critical to accurately monitor and manage preload and volemia, including invasive systemic and pulmonary blood pressure monitoring and transesophageal echocardiography. Most cases received dobutamine and adrenalin infusion to improve contractility and inhaled nitric oxide and iloprost (Ventavis®) to diminish the RV afterload, allowing a better RV function and a more rapid adaptation to the increased LV output generated by the LVAD (18). The weaning from cardiopulmonary bypass was done carefully, slowly restoring the cardiac output generated by the device from the left side of the heart. During the first 24 hours after surgery constant monitoring of signs of RV claudication was necessary to calibrate the device output to achieve an adequate clinical
Table 2 Clinical outcomes

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Operation time (min)</td>
<td>230</td>
<td>220</td>
<td>240</td>
<td>210</td>
<td>250</td>
<td>180</td>
<td>180</td>
<td>210</td>
<td>200</td>
</tr>
<tr>
<td>CPB time (min)</td>
<td>71</td>
<td>45</td>
<td>64</td>
<td>54</td>
<td>108</td>
<td>81</td>
<td>68</td>
<td>52</td>
<td>62</td>
</tr>
<tr>
<td>Concomitant procedure</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Intubation time (days)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>7</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>CCU (days)</td>
<td>10</td>
<td>7</td>
<td>7</td>
<td>5</td>
<td>23</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Hospital (days)</td>
<td>16</td>
<td>16</td>
<td>17</td>
<td>12</td>
<td>23</td>
<td>15</td>
<td>14</td>
<td>23</td>
<td>19</td>
</tr>
<tr>
<td>RPM</td>
<td>2,800</td>
<td>2,800</td>
<td>2,700</td>
<td>2,660</td>
<td>2,500</td>
<td>2,900</td>
<td>2,800</td>
<td>2,540</td>
<td>2,800</td>
</tr>
<tr>
<td>Flow (Lt/min)</td>
<td>4.5</td>
<td>5.8</td>
<td>5.4</td>
<td>6.5</td>
<td>4.1</td>
<td>5.9</td>
<td>5.6</td>
<td>4.3</td>
<td>5.7</td>
</tr>
<tr>
<td>Watts</td>
<td>4.4</td>
<td>4.6</td>
<td>4.1</td>
<td>4.2</td>
<td>3.0</td>
<td>6.0</td>
<td>4.7</td>
<td>3.1</td>
<td>4.8</td>
</tr>
<tr>
<td>LVAD support (days)</td>
<td>461</td>
<td>1,481</td>
<td>1,377</td>
<td>1,103</td>
<td>23</td>
<td>867</td>
<td>787</td>
<td>672</td>
<td>320</td>
</tr>
<tr>
<td>Actual state</td>
<td>Tx</td>
<td>LVAD</td>
<td>LVAD</td>
<td>LVAD</td>
<td>Dead</td>
<td>LVAD</td>
<td>LVAD</td>
<td>LVAD</td>
<td>Dead</td>
</tr>
</tbody>
</table>

CPB, cardiopulmonary bypass; CCU, critical care unit; LVAD, left ventricular assist device; RPM, revolutions per minute; Tx, transplant.

Table 3 Adverse events

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>&lt;90 days</th>
<th>90–180 days</th>
<th>&gt;180 days</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reexploration for bleeding (n)</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Renal dysfunction (n)</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Hepatic dysfunction (n)</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Sepsis (n)</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Driveline infection (n)</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Cerebrovascular accident (n)</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Digestive bleeding (n)</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Arrhythmias (n)</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>LVAD thrombosis (n)</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Outflow stenosis (n)</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

LVAD, left ventricular assist device.

response.
Postoperative hemorrhage is another serious complication, therefore it is considered necessary to use blood by-products, such as prothrombin complex concentrate, fibrinogen, antifibrinolytics and surgical hemostats (19). In this series, patients received prothrombin extracts (Octaplex®), to avoid blood transfusions and reduce the risk of sensitization facing transplantation (20). Another potential risk is infection,
prevention includes preoperative skin wash with antiseptics, oral chlorhexidine, nasal antibiotics and broad spectrum intravenous antibiotics (21).

Most patients evolved without major immediate postoperative events, and the median postoperative length of stay was 17 days, assuring optimum levels of anticoagulation and suitable education to patients and caregivers on the use of the equipment.

The mean follow-up was 846±479 days (range, 23–1,481 days), and has not been devoid of complications, registering a total of 20 hospitalizations.

The patient who died 23 days after surgery was the most severely ill, classified as Intermacs 1, corresponding to the group of patients reported with the highest probability of death because of poor hemodynamic conditions on other organs, that finally lead to multiorgan failure (22).

As described in literature, this group also presented different complications during follow-up, many of them requiring hospitalization, making it necessary to have a close follow-up of these patients. It is probable that future progress in device design and medical treatment will decrease the postoperative complication rate (23).

Conclusions

LVAD implantation as a “bridge to transplantation” is a strategy that has generated considerable interest in the developed world, as a product of the organ donation shortage along with improved cost-effectiveness of new devices (24,25).

This report, even if includes a small number of patients, is the largest in South America and reveals the advantages and difficulties of this important procedure, that has attained great progress but is not free of complications.

The patients described in this study represent the most important experience in minimally invasive LVAD implantation surgery as a bridge to transplantation with the longest follow-up in Chile and South America. The positive outcome of this program is a result of the cumulative experience in ES-HF management, support from successful academic exchange with the Hannover Medical School, and work done for over 20 years in short-term circulatory assistance in advanced heart failure patients (26).

Acknowledgements

The authors are particularly grateful to Professor Axel Haverich, Head of the Cardiac, Thoracic, Transplantation and Vascular Surgery Department, Hannover Medical, Professor Jan Schmitto and Dr. Sebastian Rojas, from the same institution, who gave us their full collaboration, expertise and support to achieve this successful experience.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The study was approved by the Ethics Committee of Hospital Dr. Gustavo Fricke (No. 16199).

References


